A 64-year-old with PAD and diabetes underwent fem-pop stent placement and is on rivaroxaban 2.5 mg BID plus aspirin. He asks about bleeding risk. What...

Question

A 64-year-old with PAD and diabetes underwent fem-pop stent placement and is on rivaroxaban 2.5 mg BID plus aspirin. He asks about bleeding risk. What is appropriate counseling?

Accepted Answer

There is an increased bleeding risk; benefits in reducing MACE/MALE should be balanced with patient values and risk

Answer

Bleeding risk is identical to aspirin alone

Answer

No need to monitor for bleeding

Answer

Stop therapy after 1 month to avoid bleeding

Answer

Switch to warfarin to reduce bleeding risk

us-abim MCQ (SBA): PAD (Dual-Pathway Risks)

A 64-year-old with PAD and diabetes underwent fem-pop stent placement and is on rivaroxaban 2.5 mg BID plus aspirin. He asks about bleeding risk. What is appropriate counseling?